Search results
Results from the WOW.Com Content Network
para-Methoxyphenylpiperazine (pMeOPP), also known as 4-methoxyphenylpiperazine (4-MeOPP), is a substituted piperazine derivative with stimulant effects which has been sold as an ingredient in "Party pills", initially in New Zealand and subsequently in other countries around the world. [1]
[1] [2] [4] This is in contrast to the related drug meta-chlorophenylpiperazine (mCPP), which shows high affinity for both the serotonin 5-HT 1A and 5-HT 2 receptors. [ 5 ] [ 2 ] oMeOPP and mCPP have both been found to suppress conditioned avoidance responses (CARs) without markedly affecting escape behavior in animals, indicative that they ...
Two common salts in the form of which piperazine is usually prepared for pharmaceutical or veterinary purposes are the citrate, 3C 4 H 10 N 2 ·2C 6 H 8 O 7 (i.e. containing 3 molecules of piperazine to 2 molecules of citric acid), and the adipate, C 4 H 10 N 2 ·C 6 H 10 O 4 (containing 1 molecule each of piperazine and adipic acid).
Substituted piperazines are a class of chemical compounds based on a piperazine core. [1] Some are used as ... 4-methoxyphenyl)(4-methylpiperazin-1-yl ...
1-Phenylpiperazine (1-PP or PP) is a simple chemical compound and drug featuring a phenyl group bound to a piperazine ring. [1] The suffix ‘-piprazole’ is sometimes used in the names of drugs to indicate they belong to this class. [2] It is a rigid analogue of amphetamine.
Piberaline (EGYT-475; Trelibet) is a psychoactive drug and member of the piperazine chemical class which was developed in the 1980s. It has stimulant and antidepressant effects which are thought to be due largely to its active metabolite benzylpiperazine. [1]
Trimetazidine (IUPAC: 1-(2,3,4-trimethoxybenzyl)piperazine) is a drug sold under many brand names for angina pectoris (chest pain associated with impaired blood flow to the heart). [1] Trimetazidine is described as the first cytoprotective anti-ischemic agent developed and marketed by Laboratoires Servier (France).
Bucinnazine (AP-237, 1-butyryl-4-cinnamylpiperazine) is an opioid analgesic drug that was widely used in China to treat pain in cancer patients as of 1986. [1] It is one of the most potent compounds among a series of piperazine- amides first synthesized and reported in Japan in the 1970s.